Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
50
IONS Quote, Financials, Valuation and Earnings
Last price:
$81.12
Seasonality move
:
-1.07%
Day range:
$80.06 - $82.10
52-week range:
$23.95 - $86.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.25x
P/B ratio:
21.27x
Volume:
2.8M
Avg. volume:
2.3M
1-year change:
158.85%
Market cap:
$13.1B
Revenue:
$944M
EPS (TTM):
-$2.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
|
$156.1M | -$1.22 | 48.29% | -19.88% | $93.76 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BIIB
Biogen, Inc.
|
$2.2B | $1.62 | -4.12% | 85.49% | $205.67 |
|
GERN
Geron Corp.
|
$50.4M | -$0.05 | 26.52% | -32.89% | $3.40 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 30.05% | 17.65% | $8.50 |
|
TWST
Twist Bioscience Corp.
|
$102M | -$0.52 | 16.07% | -19.61% | $49.89 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
|
$81.15 | $93.76 | $13.1B | -- | $0.00 | 0% | 14.25x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.92 | $457.00 | $44.2B | 147.50x | $0.00 | 0% | 11.97x |
|
BIIB
Biogen, Inc.
|
$191.82 | $205.67 | $28.2B | 21.78x | $0.00 | 0% | 2.95x |
|
GERN
Geron Corp.
|
$1.68 | $3.40 | $1.1B | -- | $0.00 | 0% | 6.09x |
|
MNKD
MannKind Corp.
|
$3.28 | $8.50 | $1B | 34.82x | $0.00 | 0% | 3.23x |
|
TWST
Twist Bioscience Corp.
|
$48.71 | $49.89 | $3B | -- | $0.00 | 0% | 7.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
|
83.98% | 2.779 | 20.01% | 1.79x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BIIB
Biogen, Inc.
|
26.72% | 0.777 | 25.77% | 1.70x |
|
GERN
Geron Corp.
|
-- | 1.656 | -- | 3.16x |
|
MNKD
MannKind Corp.
|
124.56% | -0.068 | 13.7% | 2.54x |
|
TWST
Twist Bioscience Corp.
|
17.69% | 0.525 | 5.04% | 3.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
|
$195M | -$215M | -14.32% | -67.97% | -105.91% | -$138.4M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BIIB
Biogen, Inc.
|
$1.5B | $372.1M | 5.34% | 7.36% | 17.06% | $401.7M |
|
GERN
Geron Corp.
|
$46.7M | -$10.8M | -18.85% | -33.5% | -22.47% | -$13.5M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
|
TWST
Twist Bioscience Corp.
|
$54M | -$32.9M | -14.09% | -16.63% | -31.73% | -$34.8M |
Ionis Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns IONS or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of 16.99%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.96.06% -$1.41 $3.1B ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About IONS or ALNY?
Ionis Pharmaceuticals, Inc. has a consensus price target of $93.76, signalling upside risk potential of 15.54%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is IONS or ALNY More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.291, which suggesting that the stock is 70.94% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock IONS or ALNY?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or ALNY?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 14.25x versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.14.25x -- $203M -$229M ALNYAlnylam Pharmaceuticals, Inc.11.97x 147.50x $1.1B $186.4M
-
Which has Higher Returns IONS or BIIB?
Biogen, Inc. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of -2.24%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat Biogen, Inc.'s return on equity of 7.36%.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.96.06% -$1.41 $3.1B BIIBBiogen, Inc.68.12% -$0.33 $24.9B -
What do Analysts Say About IONS or BIIB?
Ionis Pharmaceuticals, Inc. has a consensus price target of $93.76, signalling upside risk potential of 15.54%. On the other hand Biogen, Inc. has an analysts' consensus of $205.67 which suggests that it could grow by 7.22%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Biogen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 BIIBBiogen, Inc.14 20 1 -
Is IONS or BIIB More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.291, which suggesting that the stock is 70.94% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.160, suggesting its less volatile than the S&P 500 by 84.033%.
-
Which is a Better Dividend Stock IONS or BIIB?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or BIIB?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are smaller than Biogen, Inc. quarterly revenues of $2.2B. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than Biogen, Inc.'s net income of -$48.9M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Biogen, Inc.'s PE ratio is 21.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 14.25x versus 2.95x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.14.25x -- $203M -$229M BIIBBiogen, Inc.2.95x 21.78x $2.2B -$48.9M
-
Which has Higher Returns IONS or GERN?
Geron Corp. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of -64.86%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat Geron Corp.'s return on equity of -33.5%.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.96.06% -$1.41 $3.1B GERNGeron Corp.97.28% -$0.05 $223.6M -
What do Analysts Say About IONS or GERN?
Ionis Pharmaceuticals, Inc. has a consensus price target of $93.76, signalling upside risk potential of 15.54%. On the other hand Geron Corp. has an analysts' consensus of $3.40 which suggests that it could grow by 102.38%. Given that Geron Corp. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Geron Corp. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 GERNGeron Corp.3 1 1 -
Is IONS or GERN More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.291, which suggesting that the stock is 70.94% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.620, suggesting its less volatile than the S&P 500 by 38.038%.
-
Which is a Better Dividend Stock IONS or GERN?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or GERN?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are larger than Geron Corp. quarterly revenues of $48M. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than Geron Corp.'s net income of -$31.1M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 14.25x versus 6.09x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.14.25x -- $203M -$229M GERNGeron Corp.6.09x -- $48M -$31.1M
-
Which has Higher Returns IONS or MNKD?
MannKind Corp. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of 9.72%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.96.06% -$1.41 $3.1B MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About IONS or MNKD?
Ionis Pharmaceuticals, Inc. has a consensus price target of $93.76, signalling upside risk potential of 15.54%. On the other hand MannKind Corp. has an analysts' consensus of $8.50 which suggests that it could grow by 159.15%. Given that MannKind Corp. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe MannKind Corp. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 MNKDMannKind Corp.8 0 0 -
Is IONS or MNKD More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.291, which suggesting that the stock is 70.94% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.131%.
-
Which is a Better Dividend Stock IONS or MNKD?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or MNKD?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are larger than MannKind Corp. quarterly revenues of $82.1M. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than MannKind Corp.'s net income of $8M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 34.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 14.25x versus 3.23x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.14.25x -- $203M -$229M MNKDMannKind Corp.3.23x 34.82x $82.1M $8M
-
Which has Higher Returns IONS or TWST?
Twist Bioscience Corp. has a net margin of -112.81% compared to Ionis Pharmaceuticals, Inc.'s net margin of -29.42%. Ionis Pharmaceuticals, Inc.'s return on equity of -67.97% beat Twist Bioscience Corp.'s return on equity of -16.63%.
Company Gross Margin Earnings Per Share Invested Capital IONSIonis Pharmaceuticals, Inc.96.06% -$1.41 $3.1B TWSTTwist Bioscience Corp.52.05% -$0.50 $554.1M -
What do Analysts Say About IONS or TWST?
Ionis Pharmaceuticals, Inc. has a consensus price target of $93.76, signalling upside risk potential of 15.54%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $49.89 which suggests that it could grow by 2.42%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Twist Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings IONSIonis Pharmaceuticals, Inc.10 6 0 TWSTTwist Bioscience Corp.7 2 0 -
Is IONS or TWST More Risky?
Ionis Pharmaceuticals, Inc. has a beta of 0.291, which suggesting that the stock is 70.94% less volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.240, suggesting its more volatile than the S&P 500 by 124.046%.
-
Which is a Better Dividend Stock IONS or TWST?
Ionis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IONS or TWST?
Ionis Pharmaceuticals, Inc. quarterly revenues are $203M, which are larger than Twist Bioscience Corp. quarterly revenues of $103.7M. Ionis Pharmaceuticals, Inc.'s net income of -$229M is lower than Twist Bioscience Corp.'s net income of -$30.5M. Notably, Ionis Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals, Inc. is 14.25x versus 7.54x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IONSIonis Pharmaceuticals, Inc.14.25x -- $203M -$229M TWSTTwist Bioscience Corp.7.54x -- $103.7M -$30.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Buy
72
SEZL alert for Feb 28
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
